We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+16.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$119M
AUM Growth
+$18.2M
Cap. Flow
+$7.39M
Cap. Flow %
6.19%
Top 10 Hldgs %
33.76%
Holding
75
New
17
Increased
23
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$3.55M
2
ALKS icon
Alkermes
ALKS
+$2.93M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$2.05M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.98M
5
NKTR icon
Nektar Therapeutics
NKTR
+$1.35M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.88M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$3.03M
3
PCYC
PHARMACYCLICS INC
PCYC
+$2.34M
4
UTHR icon
United Therapeutics
UTHR
+$2.11M
5
AMGN icon
Amgen
AMGN
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 76.66%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
51
Arrowhead Research
ARWR
$12.1B
$556K 0.47%
82,133
– –
AGIO icon
52
Agios Pharmaceuticals
AGIO
$2.08B
$472K 0.4%
5,000
+584
+13% +$65.4K
MGNX icon
53
MacroGenics
MGNX
$233M
$471K 0.39%
+15,000
New +$508K
KPTI icon
54
Karyopharm Therapeutics
KPTI
$155M
$459K 0.38%
+1,000
New +$431K
OMER icon
55
Omeros
OMER
$845M
$441K 0.37%
+20,000
New +$457K
OTIC
56
DELISTED
Otonomy, Inc.
OTIC
$424K 0.36%
+12,000
New +$410K
ZGNX
57
DELISTED
Zogenix, Inc.
ZGNX
$411K 0.34%
+37,500
New +$424K
ADVM
58
DELISTED
Adverum Biotechnologies
ADVM
$405K 0.34%
+1,000
New +$423K
TLPH icon
59
Talphera
TLPH
$68M
$386K 0.32%
4,998
– –
KBIO
60
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$366K 0.31%
93,308
+25,000
+37% +$112K
GILD icon
61
Gilead Sciences
GILD
$165B
$358K 0.3%
3,651
-677
-16% -$68.7K
NHLD
62
DELISTED
National Holdings Corporation
NHLD
$349K 0.29%
+89,530
New +$391K
LITS
63
Lite Strategy Inc
LITS
$32.4M
$54K 0.05%
+1,500
New +$134K
NEPT
64
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
– –
0
– –
BIIB icon
65
CALL
Biogen
BIIB
$30.9B
– –
-120
Closed -$269K
EXAS
66
PUT
DELISTED
Exact Sciences
EXAS
– –
-50
Closed -$6K
ILMN icon
67
CALL
Illumina
ILMN
$29.5B
– –
-257
Closed -$550K
INCY icon
68
CALL
Incyte
INCY
$25.8B
– –
-886
Closed -$481K
XBI icon
69
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-62,400
Closed -$3.88M
XOMA
70
DELISTED
Xoma
XOMA
– –
-4,000
Closed -$287K
ALXN
71
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-100
Closed -$355K
PCYC
72
CALL
DELISTED
PHARMACYCLICS INC
PCYC
– –
-150
Closed -$37K
NPSP
73
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-15,471
Closed -$553K
CBST
74
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-6,502
Closed -$655K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q1 2015 Portfolio in Review

As of Q1 2015, Opus Point Partners Management held 75 positions worth $119M, up 18% from $101M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Opus Point Partners Management deployed $7.39M of net new capital in Q1 2015, opening 17 new positions and adding to 23 existing holdings. Its largest new stake was Pacira BioSciences: 34,949 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 70% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $3.03M trimmed.

  • Opus Point Partners Management's largest Q1 2015 buy was Pacira BioSciences: 34,949 shares worth $3.1M.
  • Opus Point Partners Management added most to Alkermes in Q1 2015, an estimated $2.93M increase.
  • Opus Point Partners Management's biggest Q1 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $3.03M.
  • Opus Point Partners Management fully exited State Street SPDR S&P Biotech ETF in Q1 2015, selling an estimated $3.88M.
  • Opus Point Partners Management's ten largest holdings make up 34% of its $119M portfolio in Q1 2015.
  • Opus Point Partners Management opened 17 new positions and closed 10 in Q1 2015.
  • Opus Point Partners Management's portfolio value rose 18% quarter-over-quarter to $119M.

Based on Opus Point Partners Management's 13F filing for Q1 2015, filed 18 May 2015.